Economic cost of primary prevention of cardiovascular diseases in Tanzania by Ngalesoni, Frida et al.
Economic cost of primary prevention of
cardiovascular diseases in Tanzania
Frida Ngalesoni,1,2* George Ruhago,2,3 Ole F. Norheim2 and Bjarne Robberstad4
1Ministry of Health and Social Welfare, PO Box 9083 Dar es Salaam, Tanzania, 2Department of Global Public Health and Primary Care, University
of Bergen, Kalfarveien 31, PO Box 7804, N-5020, Bergen, Norway, 3School of Public Health and Social Sciences, Muhimbili University, PO Box
65015 Dar es Salaam, Tanzania and 4Center of International Health, University of Bergen, PO Box 7804, N-5020, Bergen, Norway
*Corresponding author. Department of Global Public Health and Primary Care, University of Bergen, Kalfarveien 31, PO Box 7804, N-
5020, Bergen, Norway. E-mail: frida.ngalesoni@igs.uib.no or fngalesoni@gmail.com
Accepted 2 July 2014
Tanzania is facing a double burden of disease, with non-communicable diseases
being an increasingly important contributor. Evidence-based preventive meas-
ures are important to limit the growing financial burden. This article aims to
estimate the cost of providing medical primary prevention interventions for
cardiovascular disease (CVD) among at-risk patients, reflecting actual resource
use and if the World Health Organization (WHO)’s CVD medical preventive
guidelines are implemented in Tanzania. In addition, we estimate and explore
the cost to patients of receiving these services. Cost data were collected in four
health facilities located in both urban and rural settings. Providers’ costs were
identified and measured using ingredients approach to costing and resource
valuation followed the opportunity cost method. Unit costs were estimated using
activity-based and step-down costing methodologies. The patient costs were
obtained through a structured questionnaire. The unit cost of providing CVD
medical primary prevention services ranged from US$30–41 to US$52–71 per
patient per year at the health centre and hospital levels, respectively. Employing
the WHO’s absolute risk approach guidelines will substantially increase these
costs. The annual patient cost of receiving these services as currently practised
was estimated to be US$118 and US$127 for urban and rural patients,
respectively. Providers’ costs were estimated from two main viewpoints: ‘what
is’, that is the current practice, and ‘what if’, reflecting a WHO guidelines
scenario. The higher cost of implementing the WHO guidelines suggests the
need for further evaluation of whether these added costs are reasonable relative
to the added benefits. We also found considerably higher patient costs, implying
that distributive and equity implications of access to care require more
consideration. Facility location surfaced as the main explanatory variable for
both direct and indirect patient costs in the regression analysis; further research
on the influence of other provider characteristics on these costs is important.
Keywords Cardiovascular disease, cost analysis, diabetes, direct and indirect cost, hyper-
tension, primary prevention, sub-Saharan Africa, Tanzania
KEY MESSAGES
 Evidence-based preventive measures are crucial to limit the growing financial burden of cardiovascular disease on the
already constrained health care systems of low income countries.
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 The costs of medical primary prevention of cardiovascular disease as currently delivered in Tanzania ranges from US$30–
71 per patient per year depending on urban/rural location and health care delivery level.
 Implementing the WHO’s primary prevention guidelines for cardiovascular disease will increase these costs substantially,
warranting further evaluation of whether this approach is worth the cost.
 The high financial burden falling on patients receiving these services suggests that the distributive and equity
implications of access need further consideration.
Introduction
For more than a decade, deaths and disability related to
cardiovascular disease (CVD) in developing countries have been
overshadowed by the high burden of communicable diseases
such as HIV/AIDS (Reddy 2004). In 2010, stroke and ischaemic
heart disease accounted for about 5 million disability-adjusted
life years in the eastern, sub-Saharan region (Murray et al.
2012). Likewise, CVD deaths are increasing, currently account-
ing for 11.6% of total deaths and projected to increase to 13.4%
by 2015 (Mathers et al. 2008). The common risk factors for CVD
are well known and have been shown to be highly prevalent in
sub-Saharan Africa, including Tanzania (Dalal et al. 2011). The
overall prevalence of hypertension in the region was reported to
be 16.2% (Twagirumukiza et al. 2011) and that of diabetes has
reached 2–3% in many countries (Gill et al. 2009), including
frequencies of 3–10% in urban settings (Mbanya et al. 2010;
Hall et al. 2011). Smoking prevalence is on average 25% and the
prevalence of obesity shows a large variance, with rates
between 4% and 43% (Dalal et al. 2011). Studies published
after the year 2000 confirm the high and rising prevalence of
CVD risk factors in Tanzanian populations (Aspray et al. 2000;
Edwards et al. 2000; Njelekela et al. 2001, 2009; Bovet et al.
2002; Hendriks et al. 2012).
The burden of CVD has major social and economic conse-
quences, such as depriving families of parents and the loss of
productive lives. In 2010, the total cost attributable to CVD in
the World Health Organization (WHO) African region E region
was estimated at about US$5.7 billion (Bloom et al. 2011). In
South Africa, the overall cost of stroke and heart diseases in
2007 was estimated to be US$1250 million (Gaziano 2008).
With this compelling evidence of the rising prevalence of risk
factors for CVD, failure to act now by implementing evidence-
centred preventive measures will result in large increases of
avoidable CVD, placing enormous pressures on the constrained
health care systems of low income countries.
Preventive cardiology in the region not only receives low
priority but is also practised with a non-holistic approach
(Gaziano et al. 2005; Gaziano 2007; Sanderson et al. 2007).
These practices of focusing on single risk factors have been
shown to be less effective and more costly than management
based on the absolute risk approach advocated in the WHO
guidelines and elsewhere (Gaziano et al. 2005; Gaziano 2007;
Jackson et al. 2005; WHO 2007). In Tanzania, only implicit and
non-specific guidelines exist, with small segments addressing
the prevention of CVD (see Supplementary Appendix S1)
(Ministry of Health and Social Welfare 2000, 2008;
Association of Physicians of Tanzania 2003). Standard practice
for CVD medical primary prevention is that patients visit health
facilities (dispensary, health centre or hospital) either through
referral from a lower to a higher level of care or through
self-referral. At these facilities, depending on the level of care
(see Supplementary Appendix S1), patients are seen by phys-
icians, medical doctors or assistant medical officers, with each
visit entailing a routine blood pressure check, laboratory tests
including urine analysis, blood glucose and blood chemistry
and drug prescription when necessary. Follow-up is usually
every month or every 2 weeks depending on the patient’s
condition and the availability of drugs.
Planning and implementation of preventive strategies is
hindered by a lack of evidence on the cost of different
interventions. A literature search did not yield any cost analyses
pertaining to preventive cardiology in the region; rather, we
found an article detailing cost of diabetes studies (Mbanya and
Mbanya 2003). This article therefore aims to estimate the cost,
reflecting actual resource use, of providing outpatient medical
primary prevention measures for CVD among at-risk patients.
For the reasons highlighted above, we also aimed to estimate
the provider costs if the WHO’s medical primary prevention
guidelines (designed for low resource settings and incorporating
low levels of health facility care) were implemented in
Tanzania. In addition, the cost to patients of receiving these
services was evaluated and further explored to determine which
factors explain the main cost drivers.
Methods
This study was conducted in Arusha region, located in northern
Tanzania. Four health facilities representing different health
delivery levels (one regional hospital, one district hospital and
two health centres) were purposively selected. Two facilities
were located in Arusha municipality and the other two in
Monduli district, signifying urban and rural settings, respect-
ively. All these facilities are government owned apart from the
rural health centre which is ‘designated’, meaning that it is
partly government and partly faith-based managed. The costing
period was the Tanzanian financial year (July 2011 to June
2012).
Cost methodology
We adopted a ‘narrow’ societal perspective whereby only health
care provider and patient costs were included (Mogyorosy and
Smith 2005). Due to the lack of costing guidelines in the area of
preventive cardiology, ‘Cost Analysis in Primary Health Care’
and ‘Costing Guidelines for HIV Services’ (UNAIDS 2000, 2011)
were modified and used as a costing guide for the provider
perspective part of the study. We used an ingredients approach
to costing to identify and measure all providers’ resource use.
Detailed interviews were held with key personnel at the
outpatient and other supporting departments in each health
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facility in order to identify the standard service pathways for
patients at risk of CVD. In addition, we also inspected order
books, inventory records, issue vouchers and delivery notes so
as to record all the equipment and supplies consumed.
Administrators and hospital accounts were consulted to deter-
mine resources used at the administrative level and overhead
costs. Whenever necessary, physical counting of equipment and
supplies was performed. Health Management and Information
Systems (HMIS) books and other relevant hospital records were
used to collect data on the number of patients and visits,
laboratory tests done and drugs dispensed during the costing
period.
Cost valuation followed the economic (opportunity) costs
approach (Gold et al. 1996; Drummond et al. 2005), whereby all
resources are valued at the cost of their best alternative use.
Data on the cost of medical supplies and equipment were
based on the Tanzania Medical Stores Department (MSD)
price catalogue (Medical Stores Department and Tanzania
2011\2012). We used the Tanzania Government Procurement
Services Agency tender prices for other non-medical equipment
and supplies. Rental charges for buildings were calculated
according to National Housing Corporation (NHC) rates. The
prevailing market price was used as proxy for items whose
prices were unavailable from the data sources named above. All
costs were estimated in Tanzanian shillings (TSh) and con-
verted to US$ using a mean exchange rate of 1609 TSh/US$
(Bank of Tanzania 2012a) for the financial year 2011/2012.
Exit interviews were conducted to a total of 100 patients from
the 4 study facilities using a structured questionnaire (see
Supplementary Appendix S2) to obtain patient costs. These
were adults aged 30 years who had been diagnosed with
hypertension and/or diabetes at least 6 months prior to the
interview. After probing for patients’ alternative time use,
market prices for agriculture and livestock products and
Tanzanian minimum wages were used to value lost productive
working hours during which patients are at health facilities
receiving CVD preventive services. Finally, regression models
were built to explore the relationships between relevant
dependent and independent patient cost variables.
Cost analysis
Providers’ cost analysis was performed using Excel. All relevant
health facility departments were grouped into direct, inter-
mediate, supporting and administration service centres depend-
ing on whether they had direct patient contact or facilitated,
supported or provided services necessary for a facility to
function. Resource use was then classified as financial and
economic costs and later grouped under capital or recurrent
costs. Capital costs consist of items like buildings and equip-
ment whose useful life exceeds a year, while recurrent costs
include salaries and supplies.
Capital costs were annuitized using a rate of 9.6%, which was
the average interest rate for the year 2011/12 reported by the
Bank of Tanzania (2012b) and their useful life years were based
on WHO assumptions (WHO 2012a). Capital items costing less
than US$62 (TSh100 000) were treated as recurrent costs.
For each direct service centre, total financial and economic
costs were calculated and apportioned to the intervention of
interest using personnel time. Subsequently, a three-stage,
step-down costing methodology (Conteh and Walker 2004;
Drummond et al. 2005; Fleßa 2009) was used to allocate shared
and overhead costs to the different service centres. First, costs
were estimated and apportioned using an activity-based ap-
proach reflecting actual resource use (UNAIDS 2000, 2011);
second, overhead service centre costs were allocated to sup-
porting, intermediate and direct service centres. The accrued
costs of the indirect service centres were then apportioned in
the same manner until all costs were assigned to direct service
centres (see Supplementary Appendix S3). Depending on the
service centre being apportioned to, the total number of health
facility visits, outpatient visits, CVD outpatient visits or CVD
outpatients was used as the allocation keys. Finally, the total
cost of the direct service centres was divided by the total
number of CVD outpatients seen and total number of CVD
visits made to derive the unit cost per patient and per visit.
Uncertainty was managed by performing sensitivity analysis
assuming 20% change around input prices (Mogyorosy and
Smith 2005). In line with variability around drug prices,
scenario analysis was performed to test changes in providers’
unit cost when other valuation sources are applied.
Table 1 summarizes the recommendations of the WHO
primary prevention of CVD guidelines after applying the risk
prediction charts (WHO 2007). To estimate the cost required for
its medical interventions implementation, we made the follow-
ing assumptions in addition to these basic recommendations
(Table 1). First, we assumed the same facility setup will be used
and that upgrading of infrastructure is not required.
Second, health centre levels were deemed incapable of
performing cholesterol tests or managing patients with a 10-
year risk of CVD above 20% and thus these tests and patients
were not included in the costing at this level. This is in
accordance with the structure and capabilities of facility levels
in Tanzania.
Third, for simplicity, two anti-hypertensives—thiazide diur-
etics as monotherapy and thiazide diuretics and angiotensin-
converting enzyme inhibitors (ACEI) as duotherapy—are con-
sidered in the cost estimates (Wright and Musini 2009).
However, for CVD risk patients with diabetes, ACEI and
calcium channel blockers are costed due to contraindications
for thiazide diuretics (Lemogoum et al. 2003; Grossman and
Messerli 2011). Fourth, although glibenclamide is not directly
recommended in the WHO guidelines it is considered in
combination with metformin as duotherapy. This is because
this drug is very likely to be available in low resource settings
and it is mentioned in the pocket version of the WHO
guidelines and elsewhere in the subsequent WHO reports for
non-communicable disease management and control (WHO
2012b).
Patient cost data entry was done using EpiData software
version 3.1. Descriptive and regression analyses were carried out
using STATA 12. For descriptive analysis, summary statistics
such as mean and standard deviation were computed and the
Wilcoxon–Mann–Whitney rank sum test done. This non-
parametric rank test was necessary due to positively skewed
cost data. Two types of regression models were applied:
multiple linear regression and logistic regression, with the
outcome variables of choice being those which showed signifi-
cant differences between facility locations. These were: cost of
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food, laboratory test and prescribed drugs and travel and
waiting time. The remaining cost items, named cost of travel
and consultation, total costs and loss of income, were con-
sidered as secondary outcome variables.
We hypothesized that the cost of receiving health care depends
on several factors, including socioeconomic factors, CVD risk
duration, household location and the facility’s geographical
location. These were therefore examined as explanatory variables.
Our descriptive regression analysis started by examining the
statistical association of each independent variable on the
outcome variables (Model 1). We also tested for normality of
residuals and in many instances, a log transformation of
variables was necessary due to the non-normality of residuals.
After testing for multicollinearity, we included into the
multiple regression analysis only those variables that were
independently associated with the outcome variables (Model 2).
Some outcome variables with obvious relevance to other
outcome variables were included directly as regressors, e.g.
travel time and cost of travel. We then ran a backward stepwise
regression beginning with a full model, as a means of variable
selection into the final model, in which we include significant
and exclude insignificant independent variables according to
the inclusion and exclusion criteria set at significance levels of
5% and 10%, respectively.
Results
Health facility cost of preventive cardiology
Tables 2–4 present total facility costs, unit costs and some key
output statistics for CVD primary prevention as it is currently
delivered at these four Tanzanian health facilities (Excel sheets
presenting quantities of resource use and their unit prices are
available from the authors upon request).
The observed annual costs of providing these services were
higher at the hospital level than the health facility level. The
cost per patient ranged from US$30–41 to US$52–71 per patient
per year at the health centre and hospital levels, respectively.
We did not observe marked differences in the unit cost per visit
for urban facilities.
Outpatient departments were shown to be the main con-
tributors to the total costs (59–86%), and in all facilities except
the rural hospital, laboratory services were the second largest.
No substantial differences were noted in the distribution
between capital and recurrent cost categories. In all the facilities,
recurrent costs represented about three quarters of the total
costs, with personnel representing the main cost driver.
Mixed results were observed in the case of unit cost
estimates, whereby cost per visit was higher (US$8.8 vs
US$7.8) and cost per patient lower (US$52 vs US$71) in rural
facilities compared with urban facilities.
Cost estimates of providing medical primary
prevention of CVD according to the WHO guidelines
From Table 5, absolute risk management according to the WHO
guidelines will require an addition of US$71 for very high-risk
patients at the hospital level and US$4 for low-risk patients at
the health centre level. Assuming that very high-risk and high-
risk patients are managed at hospital level, this translates, on
average, to almost double the cost per patient compared with
current practice if other cost items except laboratory monitoring
and drugs remain constant. However, the additional cost
required for this strategy is not substantial for low-risk patients
if managed at the health centre level.
Sensitivity and scenario analyses
Cost per patient ranged from US$28–43 to US$49–74 for health
centre and hospital level, respectively, when input prices varied
by 20%. Both unit cost per patient and per visit estimates were
robust to changes in drug valuation source from the Tanzanian
MSD to median supplier drug prices of the International Drug
Price Indicator Guide (Management Science for Health 2012). In
all health facilities, unit costs decreased by 0.3% except in the
urban health centre which saw a 0.5% increase when the latter
was used. Implementing the WHO’s CVD medical preventive
guidelines will require on average US$39 more per patient—a 2%
increase from the estimates seen when the Tanzanian MSD was
used.
Direct patient costs
Table 6 displays the costs incurred by patients in receiving
medical treatment to prevent CVD. Reported below are the
results for health facilities paired in their respective urban/rural
settings since no major differences in costs were observed
between facility levels in the same region. The main cost drivers
differed depending on the facility’s location, with the cost of
Table 1 WHO CVD primary prevention management and risk profile monitoring recommendations
Ten-year risk level
for a CVD event
Anti-hypertensive
drugs
Lipid-lowering drugs Hypoglycaemic drugs Anti-platelet
drugs
Risk profile
monitoring
<10% Lifestyle managementa Lifestyle managementa Lifestyle managementa None Every 12 months
10% to <19.9% Metformin
20 to 29.9% Thiazide diuretics,
angiotensin-converting
enzyme inhibitors,
calcium channel
blockers
Lipid-lowering drugs
(simvastatinb)
Every 6 months
>30% Soluble aspirin Every 3 months
Source: WHO (2007).
aLifestyle management entails advice on diet, exercise and lifestyle, including smoking and alcohol intake.
bSimvastatin is the only off-patent lipid-lowering drug available at the MSD of Tanzania.
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prescribed medication being prominent in the urban facilities
while the cost of food recorded highest in rural facilities. The
differences in cost were shown to be statistically significant at
the 5% level, except for travel and consultation costs.
Indirect patient costs
Presented in Table 6 are estimates of income loss due to
working hours lost while receiving medical preventive services.
Fifty-five per cent of all patients in our sample reported that
their income had been affected as a result of receiving these
health services. Rural residents lost more income due to
absence from productive work, although this difference was
not statistically significant. As for the indirect costs of waiting
and travel time, patients attending urban facilities had to wait
twice as long (mean waiting time of 4 h for urban facilities)
compared with those in rural facilities (P¼ 0.0001).1 Even
Table 2 Annual hospital costs of providing primary prevention services for CVD as currently delivered in Tanzania, 2012 (US$)
Urban Rural
OPD Lab Pharm Other Total OPD Lab Pharm Other Total
Capital costs
Buildings 6147 544 1126 1027 8844 543 54 54 43 694
Equipment 697 311 105 115 1228 116 21 11 12 160
Training 2944 0 0 0 2944 1650 0 0 0 1650
Total capital costs 9788 855 1231 1142 13 016 2309 75 65 55 2504
Recurrent costs
Personnel 19 866 4555 1943 3940 30 304 3449 559 496 528 5032
Drugsa 0 0 3120 0 3120 0 0 797 0 797
Lab consumables 0 3888 0 0 3888 0 218 0 0 218
Supplies 1062 135 74 394 1665 181 55 31 141 408
Building operations 0 0 0 2049 2049 0 0 0 61 61
IEC materials 2844 0 0 0 2844 2371 0 0 0 2371
Total recurrent costs 23 772 8578 5137 6383 43 870 6001 832 1324 730 8887
Total 33 560 9433 6368 7525 56 886 8310 907 1389 785 11 391
Notes: Exchange rate 1US$¼ 1609 TSh.
IEC, information, education and communication; Lab, laboratory; OPD, outpatient department; Other, supporting departments (medical stores, medical records
and laundry) and administration; Pharm, pharmacy.
aDrugs included here are oral anti-hypertensives and oral hypoglycaemic drugs; statins and low-dose aspirin were not consumed.
Table 3 Annual health centre costs of providing primary prevention of CVD as currently delivered in Tanzania, 2012 (US$)
Urban Rural
OPD Lab Pharm Other Total OPD Lab Pharm Other Total
Capital costs
Buildings 198 30 13 81 322 113 66 61 59 299
Equipment 18 2 1 4 25 16 6 7 13 42
Training 821 0 0 0 821 732 0 0 0 732
Total capital costs 1037 32 14 85 1168 861 72 68 72 1073
Recurrent costs
Personnel 1451 80 54 153 1738 606 303 170 425 1504
Drugsa 0 0 38 0 38 0 0 98 0 98
Lab consumables 0 129 0 0 129 0 140 0 0 140
Supplies 127 21 1 10 159 49 32 7 68 156
Building operations 0 0 0 23 23 0 0 0 20 20
IEC materials 1422 0 0 0 1422 949 0 0 0 949
Total recurrent costs 3000 230 93 186 3509 1604 475 275 513 2867
Total 4037 262 107 271 4677 2465 547 343 585 3940
Notes: Exchange rate 1US$¼ 1609 TSh.
IEC, Information, education and communication; Lab, laboratory; OPD, outpatient department; Other, supporting departments (medical stores, medical records
and laundry) and administration; Pharm, pharmacy.
aDrugs included here are oral anti-hypertensives and oral hypoglycaemic drugs; statins and low-dose aspirin were not consumed.
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though travel costs were higher in the rural region, travel time
was significantly shorter (P¼ 0.015)1 compared with the urban
region, by an average of 20 min.
Patient cost regression analysis results
Stepwise regression analysis results for each of the six outcome
variables, with insignificant variables omitted (see Supplementary
Appendix S4), shows that younger patients (<40 years old) paid
50% more for drugs (P¼ 0.042) compared with other age groups
(40–59 and >60 years old). The cost of drugs was also
significantly higher for patients attending urban facilities, by
55% (P¼ 0.001). CVD risk duration and socioeconomic status did
not significantly explain the cost of drugs. Even though respond-
ents stated a preference for more hospital visits as a reason to
avoid buying drugs, the model results showed an insignificant
contribution from this explanatory variable (Table 7).
Facility’s geographical location was not a significant explana-
tory variable for cost of food or laboratory tests, in contrast to
the rank test results in Table 6. Waiting time was not
significantly explained by travel time. Patients attending
urban facilities had to wait and travel longer than rural facility
attendees (Table 7). Patients attending urban facilities and
those having had CVD risk factors for more than 2 years
decreased the log odds of frequent clinic visits compared to
patients attending rural facilities and newly diagnosed. This
probability of more visits was increased in patients younger
than 40 years. The model results did not reveal a negative
influence from cost of drugs, waiting or travel time on
frequency of clinic visits.
Patient cost uncertainty
Patient costs seem to be uncertain, with long 95% confidence
intervals for total cost. According to the standard deviations
presented in Table 6, total annual cost per patient ranged from
US$14–223 to US$10–245 in the urban and rural settings,
respectively.
Discussion
This work sets out to estimate the cost of primary medical
prevention of CVD from two perspectives, the providers’ and
the patients’. The providers’ viewpoint was first analyzed
according to current practice and then, additionally, we
estimated costs assuming a scenario in which the WHO’s
medical primary prevention of CVD guidelines are being
followed. To the best of our knowledge, this is the first study
in the sub-Saharan context to evaluate the cost of primary
medical interventions to prevent CVD.
Several main findings emerged from this study. First,
utilization rates and bypassing of the health referral system
drive the unit costs. Second, cost estimates indicate that
implementing the WHO’s medical primary preventive guidelines
more than doubles the costs of current practice—assuming
other cost items remain constant—warranting further evalu-
ation. Third, even though health services are free at the point of
use for patients with chronic diseases in Tanzania, the cost of
medication is shown to be among the main patient cost drivers.
Additionally, the geographical location of health facilities
Table 4 Annual health facility output statistics and unit costs of providing primary prevention of CVD as currently delivered in Tanzania (service
units in parentheses)
Urban Rural
Hospital Health centre Hospital Health centre
Facility output by department Number
Outpatient department (CVD visits) 7 323 631 1 298 558
Outpatient department (CVD patients) 802 158 217 95
Outpatient department (all visits) 75 435 87 923 47 906 11 638
Laboratory department (tests) 26 443 3 946 1 722 4 004
Total health facility (visits) 114 828 87 923 55 390 12 622
Unit costs by service centre (patients) 2012, US$
Outpatient department 41.8 25.5 38.3 25.9
Laboratory department 11.8 1.7 4.2 5.8
Pharmacy department 7.9 1.1 6.4 3.6
Supporting department and administration 9.4 1.8 3.6 6.2
Unit costs per patient/visit—all service centres 2012, US$
Cost per patient 71 30 52 41
Cost per visit 7.8 7.4 8.8 7.1
Table 5 Estimated additional annual cost per patient of implementing
WHO primary prevention of CVD guidelines, 2012 (US$)
Hospital level Heath centre level
Ten-year CVD risk Very high
risk
High
risk
Moderate
risk
Low
risk
>30% 20–29.9% 10–19.9% <10%
Cost of medication 55 36 29 —
Cost of laboratory
risk profile
monitoring
16 8 4 4
Total 71 44 33 4
Notes: Exchange rate: 1US$¼ 1609 TSh.
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influenced most of the patients’ costs, indicating the need for
further research into the role of other provider characteristics in
explaining these costs.
Total cost and unit costs at hospital level were expected to be
higher than those of health centres. This is because hospitals are
planned for the management of severe and complex cases and
therefore requires sophisticated diagnostic services and equip-
ment, specialized clinical experts and they generally have higher
over heads than low-level facilities. However, it is worth noting
that cost per visit estimates were not so different at the two
delivery levels for the urban facilities. One plausible explanation
could be the common phenomenon of the bypassing of lower
level facilities, with the most cited reason being the perceived
higher quality of care, for instance, availability of drugs at higher
level facilities (Harpham and Molyneux 2001; Klemick et al.
2009). This implies that health centres may be underutilized, and
the hospital level is likely to be managing low-risk patients
instead of concentrating on those at high risk, hence decreasing
efficiency and increasing costs for these facilities. More space for
resource saving is therefore possible if patients with moderate-to-
low CVD risk levels are attended at lower level facilities.
The availability of many and highly qualified personnel
(Munga and Mæstad 2009), advanced equipment and func-
tional laboratories makes it probable that total costs will be
higher in urban than in rural facilities, as is shown in our study
results. For example, laboratory costs for the urban hospital are
seven times higher than those of its rural counterpart. Unit
costs, on the other hand, portrayed mixed results in this case.
This could again be explained by the factors of referral bypass
for urban facilities highlighted above, meaning that these
hospitals are receiving many visits from patients who could be
managed at health centres, hence driving down the cost per
visit. Dissimilarities in the organization of the health centres
costed here (purely public in the case of the urban health centre
compared with a designated facility—church owned—for the
rural health centre) may make comparisons challenging in our
case. Designated facilities have higher standards of care
(reflected here in their higher laboratory and drug costs) than
is usual in public facilities.
The structured medical management of patients according to
the WHO’s guidelines will require more resources to implement
Table 6 Annual direct and indirect patient costs, 2012 (US$)
Urban facilities Rural facilities
Number of observations¼ 65 Number of observations¼ 35
Mean SD Minimum Maximum Mean SD Minimum Maximum P valuea Probability
(rural > urban)
Direct costs
One-way travel costb 14.0 16.2 0.0 74.6 24.6 32.9 0.0 139.2 0.4409 0.549
Cost of food 27.3 19.8 5.0 89.5 39.6 18.1 14.9 89.5 0.0003 0.720
Medical consultation costc 1.3 3.4 0.0 14.9 0.9 2.3 0.0 7.5 0.6749 0.484
Cost of laboratory tests 1.1 3.0 0.0 12.4 2.8 3.1 0.0 7.5 0.0004 0.667
Cost of prescribed drugs 51.1 34.7 0.0 139.2 28.8 24.8 0.0 101.4 0.0013 0.305
Indirect costs
Loss of income 23.3 26.3 0.0 79.6 30.3 28.5 0.0 74.6 0.2120 0.572
Total costs 118.2 53.3 31.4 307.6 127.3 59.8 44.7 245.1 0.3292 0.559
Notes: Exchange rate 1US$¼ 1609 TSh.
SD¼ standard deviation.
aP value of Mann–Whitney U test due to a non-normal data distribution.
bTravel costs for 13 patients residing in the rural region but attending urban facilities were omitted as these were outliers, including them makes the mean cost
for urban facilities 20.9.
cAll diabetic patients and patients over 60 years of age are exempted.
Table 7 Patient cost regression model results
Primary outcome variables
Explanatory variables  coefficient P value Confidence
interval
Cost of drugs (n¼ 87)
Age 40 years 0.500 0.042 0.018 to 0.981
Urban facilitiesa 0.553 0.001 0.277 to 0.829
Cost of food (n¼ 100)
Frequent clinic visitsb 0.695 0.001 0.466 to 0.923
Cost of laboratory tests (n¼ 27)
Time to diagnosisc 0.455 0.009 0.785 to 0.125
Formal educationd 0.447 0.016 0.900 to 0.006
Waiting time (n¼ 100)
Urban facilitiesa 1.630 0.001 1.135 to 2.124
Travel time (n¼ 100)
Travel cost 0.173 0.007 0.048 to 0.297
Frequent clinic visitse (n¼ 72)
Age < 40 years 2.169 0.032 4.877 to 0.499
Time to diagnosisc 2.680 0.005 4.534 to 0.825
Urban facilitiesa 2.793 0.001 4.132 to 1.454
aUrban relative to rural facilities.
bFrequent (7) relative to infrequent (6) clinic visits.
cTwo years or more since diagnosis relative to less than 1 year.
dFormal relative to informal education.
eBinary outcome variable: frequent visits is 7 to maximum and infrequent
visits is 6 to minimum.
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than those currently allocated. More resources are dedicated to
patients with a 10-year CVD risk level above 20% due to their
high drug requirements and frequent risk profile monitoring. As
will be pointed out in the limitations later, part of the cost
estimates of current practice may be explained by inefficiencies
and so, assuming that implementing such guidelines will reduce
inefficiencies by, among other things, minimizing unnecessary
visits, then the extra amount needed could be lower than the
annual US$38 per patient estimated by this work. If this scenario
is partly or wholly absorbed by government facilities, it will
decrease part of the patients’ financial burden, especially private
expenditure on drugs. It is worth noting that if public facilities are
frequently out of drugs—as is currently observed—the discrepan-
cies between drug availability and demand will increase.
In Tanzania, public health care services are ‘free’ for patients
>60 years of age, those with chronic diseases and the poor.
However, our study results suggest that financial protection from
such costs by public health facilities seems to be a far cry from
reality, especially for non-communicable diseases, which are
traditionally not prioritized in low-income countries. This study
has shown that private expenditure on medication surfaces as
one of the main drivers of direct patient costs for urban residents
(an average of US$51 per patient per year) and second highest for
rural residents (at US$29 per patient per year). The obvious
reason for the high out-of-pocket (OOP) expenditure on drugs in
this setting is the frequently empty drug shelves in government
facilities. The easy accessibility of newer drug classes in private
pharmacies in urban areas may explain the high expenditure on
drugs by urban patients. Moreover, it was found that pharma-
ceutical marketing personnel have an influence on the prescrip-
tion patterns of drugs, making it probable that prescribed
medications are not selected from the cheaper national essential
drug list, and hence impacting on the high cost of drugs to
patients (Mori et al. 2013).
In rural areas, travel and food costs contributed substantially
to direct patient costs; this finding is similar to those of other
studies reporting such costs to be the greatest barriers to
obtaining health services (Ensor and Cooper 2004; Peters et al.
2008). Lost income was also higher in this location (although
the difference was statistically insignificant) and this could be
due to having more patients engaged in agriculture and/or
working with livestock, whose sales depend on specific market
days which might fall on clinic days, compared with employed
work or daily market days in the urban region.
The current gross domestic product per capita for Arusha
region is US$413 (National Bureau of Statistics 2011), implying
that patients in this study spend on average 30% of their
annual income on receiving CVD preventive services. It can be
argued that our (hospital rather than community) patient
sample may be assumed to have a higher than average health-
seeking behaviour and hence their expenditure per capita on
medical care is high, making this percentage likely to be lower
in the general population. Nevertheless, the fact that patients
are spending more than 10% of their annual income on CVD
prevention alone is alarming. Such a high financial burden on
patients might have an impact on their health-seeking behav-
iour and hence lead to low utilization of health services and
poor compliance with treatment for these chronic illnesses
(Mendis et al. 2004; Bovet et al. 2008).
Of all the outcome variables in the patient costs regression
analysis, facility location has been shown to significantly
explain most of these costs. Interestingly, urban facility location
has both a positive and a negative effect (Table 7). The positive
influence on cost of drugs and waiting time may be explained
by the influence of pharmaceutical marketing on observed
prescription patterns and the bypassing of the health referral
system highlighted above. Its negative effect on the frequency
of clinic visits may indicate that issues of perceived poor health
care quality in rural areas (Harpham and Molyneux 2001;
Klemick et al. 2009) and problems with the full implementation
of decentralization in Tanzania’s health sector (Munga et al.
2009; Maluka et al. 2011) are important contributors. The
resource management mandate from central government to
district councils is not substantial enough to allow them to
make practical decisions about, for example, drug stocking.
Further research on the possible role of other provider charac-
teristics in explaining both facility and, importantly, patient
costs needs to be explored.
Uncertainty around patient costs is startling. Annual cost
incurred per patient was as little as US$10 and US$14 to as
high as US$245 and US$223 for rural and urban facilities,
respectively. Outliers, especially in travel and accommodation
costs for patients residing in the rural areas but attending
urban facilities, could partly explain this. More so though, these
huge differences could be motivated by recall bias. Use of better
methodology, like diaries to record costs incurred, could be
more useful in estimating more accurate values.
Strengths and limitations
Several strengths can be noted in this work. First, we took both
provider and patient perspectives, a viewpoint which enables a
reflection on the distribution of the financial burden and helps to
detect cost shifting between different segments of society.
Second, the ingredients approach to costing employed in this
study is considered to be more informative than other methods,
for example reference costing, due to its detailed primary data on
actual resource use. Finally, since chronic patients do not usually
pay user fees and OOP drug payments were mainly made in
private pharmacies, double counting was largely avoided.
This study also has some limitations. First, because of the
small number of facilities, which were not randomly selected,
the results cannot be used to make broad generalizations about
urban/rural differences or differences in costing structures
between levels of health service delivery. More research is
needed to better predict the cost implications at different
service levels if preventive cardiology is scaled up in Tanzania
and to better understand how costs may influence service
utilization by different groups within the population.
Nonetheless, given that these facilities are public and resource
inputs are centrally purchased within government-owned
bodies (MSD, NHC, government salary scales, etc.), regional
and zonal generalizations can cautiously be made. Second, part
of the provider perspective costing was based on current
practices; these could be inefficient, leading to an overesti-
mation of costs. However, given the African context of
resource-constrained health systems, overestimation may be
unlikely. Third, blunt interpretation of the unit cost results are
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discouraged since information from the HMIS books—from
which unit costs are based—is expected to be of mixed quality.
To minimize this uncertainty, we cross-checked these data
using other HMIS books and patient log books present at each
patient care service centre.
Finally, the stepwise regression method used in the patient
cost data is not without problems (Campbell 2008), as such,
results need to be interpreted with caution since some variables
coded as dummies may be lost in the model fitting, changing
the interpretation of other controlled variables; however, as
stated above, the analysis was undertaken for descriptive and
not confirmatory purposes.
Conclusion
This study estimated providers’ costs of CVD medical primary
prevention services from two main viewpoints: what is, that is
the current practice, and what if, reflecting the WHO guidelines
scenario, in four health facilities. We further determined the
direct and indirect costs to patients of receiving such services in
Tanzania. Utilization rates appear to influence the current
practice cost estimates, suggesting that appropriate use of lower
level facilities is important to ensure proper resource allocation
and more efficient CVD prevention. At this point, implementing
the WHO guidelines is more costly than the current Tanzanian
practice for patients at all risk levels except lowest and so it is
important to answer questions about whether it is worth
pursuing this approach relative to its additional benefits. The
study results also reveal considerably high patient costs,
indicating that the distributive and equity implications of
access to care need further consideration. A substantial under
estimation of the total cost of these interventions at the societal
level is likely when patient costs are ignored. The geographical
location of facilities is an important determinant of patient
costs, and further research is required to better understand the
influence of other provider characteristics on these costs and
how best to scale up these interventions in Tanzania.
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Endnote
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